Mylan Escapes Novartis MS Drug Patent Suit

Law360 (June 17, 2019, 7:11 PM EDT) -- Mylan Pharmaceuticals Inc. was able to evade a patent suit from Novartis seeking to block generic versions of its multiple sclerosis drug Gilenya when a judge said Monday that Delaware federal court isn't the right venue for the case.

U.S. District Judge Leonard P. Stark granted MPI's motion to dismiss, saying the court was not the correct venue for the case as it is presently pled. While Novartis had pointed to a single MPI employee that works in Delaware, the judge said that Novartis hasn't claimed MPI stores its materials at that worker's home or that MPI — which is a...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Attached Documents

Related

Sections

Case Information

Case Title

Subscribers Only

Case Number

Subscribers Only

Court

Delaware

Nature of Suit

Patent - Abbreviated New Drug Application(ANDA)

Judge

Subscribers Only

Date Filed

July 16, 2018

Law Firms

Companies

Government Agencies

Patents